We use cookies for a better user experience. Read our Privacy Policy

I Agree

Pseudomonas Aeruginosa Infection Treatment Market

Pseudomonas Aeruginosa Infection Treatment Market (Medication Type: Monotherapy and Combination Therapy; Drug Type: Aminoglycoside, Cephalosporin, Carbapenem, Monobactam and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Pseudomonas Aeruginosa Infection Treatment Market Outlook 2031

  • The global pseudomonas aeruginosa infection treatment market was valued at US$ 1.3 Bn in 2021
  • It is estimated to rise at a CAGR of 6.6 % from 2022 to 2031
  • The global pseudomonas aeruginosa infection treatment market is expected to reach US$ 2.5 Bn by the end of 2031

Analysts’ Viewpoint on Pseudomonas Aeruginosa Infection Treatment Market Scenario

The pseudomonas aeruginosa infection treatment market is estimated to advance considerably during the forecast period due to an increase in occurrence of a wide range of infections globally. For instance, according to NCBI, high prevalence of pseudomonas aeruginosa infections is likely to cause a surge in the demand for treating pseudomonas aeruginosa infections in the next few years. The market grew during COVID-19, as some of the patients that underwent treatment in hospitals and other healthcare facilities for COVID-19 had acquired pseudomonas aeruginosa infections due to usage of ventilators and other medical devices. Therefore, pseudomonas aeruginosa infection treatment medications, such as oral ciprofloxacin which was used to treat the patients who had COVID-19, were also used to treat pseudomonas aeruginosa infections. Furthermore, according to the WHO reports, infections caused by pseudomonas aeruginosa carbapenem resistant strains have been listed under high risk category, which states that the need for treatment is projected to increase and consequently, boost the pseudomonas aeruginosa infection treatment market growth in the near future.

Pseudomonas Aeruginosa Infection Treatment Market

Pseudomonas Aeruginosa Infection Treatment Market Introduction

Pseudomonas aeruginosa is a type of bacteria that can cause infections in individuals after they undergo a surgery. Infection can occur in the blood, lungs, or other parts of the body. Pseudomonas aeruginosa infection treatment includes various medications, therapies, and procedures that can reduce the infection caused to an individual. Pseudomonas aeruginosa infection is generally treated through antibiotics and other drugs.

The global pseudomonas aeruginosa infection treatment market size is estimated to increase significantly during the forecast period owing to an increase in prevalence of pseudomonas aeruginosa, surge in awareness about the disease, adoption of expansion strategies, and robust pipeline of new therapeutic in clinical trials

Request a sample to get extensive insights into the Pseudomonas Aeruginosa Infection Treatment Market

Increase in Incidence of Nosocomial Infections to Boost Market

Rise in prevalence of nosocomial infections associated with P. aeruginosa, such as pneumonia, urinary tract infections (UTI), cystic fibrosis, and blood stream infections, is likely to augment the global pseudomonas aeruginosa infection treatment market during the forecast period.

Increase in incidence of bacterial infections, i.e., Pseudomonas aeruginosa infections, in intensive care with no effective treatment is projected to drive the demand for newer antibacterial drugs and antibiotics for pseudomonas aeruginosa infection treatment.

According to Centers for Disease Control and Prevention (CDC) estimates, around 51,000 health care-associated P. aeruginosa infections occur in the U.S. each year. More than 6,000 (13%) of these are multidrug-resistant, with roughly 400 deaths per year attributed to these infections.

Rapid Rise in Antibacterial Drug Resistance to Augment Market

Antibacterial drug resistance is growing rapidly across the world, as it is in the nature of bacteria to develop resistance. This has generated the urgent need of new research and innovation in the antibacterial field.

According to U.S. Centers for Disease Control and Prevention (CDC) estimates, antibacterial resistance is responsible for over 2 million infections and 23,000 deaths in the U.S. each year and an estimated 25,000 deaths due to antibacterial-resistant infections in Europe. Hence, demand for newer broad spectrum antibacterial drugs is rising. There is always a need of antibacterial drugs for the treatment of children with fatal sepsis and severe pneumonia.

Request a custom report on Pseudomonas Aeruginosa Infection Treatment Market

High Demand for Combination Therapy for Pseudomonas Aeruginosa Infection Treatment

In terms of medication type, the global pseudomonas aeruginosa infection treatment market has been bifurcated into monotherapy and combination therapy. The combination therapy segment held around 74% of the global pseudomonas aeruginosa infection treatment market share in 2021. The segment is likely to maintain the status quo during the forecast period. The segment growth is due to increased drug resistance in monotherapy, which has resulted in a rise in the demand for combination therapy for the treatment of P. aeruginosa infection.

Combination therapy helps increase compliance, synergy, and efficacy, and reduce side-effects and cost. These factors are projected to boost the combination therapy segment. Additionally, rise in demand for combination therapy for treatment of pseudomonas aeruginosa infection is attributed to rapid onset of action, high bioavailability rate, cost saving, and high efficiency.

Focus of Major Pharmaceutical Companies on Development of New Class of Cephalosporin Drugs

In terms of drug type, the global pseudomonas aeruginosa infection treatment market has been classified into aminoglycoside, cephalosporin, carbapenem, monobactam, and others.

The cephalosporin segment held a major share of around 40% in 2021. It is estimated to maintain the status quo during the forecast period. Expansion of the segment can be attributed to the focus of major pharmaceutical companies on the development of new class of cephalosporin for the treatment of various P. aeruginosa infections. This is expected to fuel the growth of the cephalosporin segment.

New cephalosporin (fifth-generation) was developed for the treatment of gram negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. Launch of new cephalosporin class of drugs is likely to boost the segment.

Intravenous is Preferred Route of Administration for Pseudomonas Aeruginosa Infection Treatment

In terms of route of administration, the global pseudomonas aeruginosa infection treatment market has been split into nasal, oral, and intravenous.

The intravenous segment held a major share of around 40% in 2021. The segment is projected to grow and maintain its position during the forecast period due to the availability of the drugs for intravenous route, high accuracy in dosing, and rapid onset of action as compared to other routes.

Most physicians prefer intravenous route for administration of drugs because the entire administered dose reaches the systemic circulation, immediately, resulting in rapid onset of action against bacteria. This factor is expected to augment the segment.

Well-developed Infrastructure and Growth in Adoption of New Products Augmenting Hospital Pharmacies Segment

In terms of distribution channel, the global pseudomonas aeruginosa infection treatment market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment held a major share of around 46% of the global market in 2021. The segment is projected to grow during the forecast period due to an increase in the number of multi-specialty hospitals in developing countries. Additionally, well-developed infrastructure and increase in adoption of new products by hospital pharmacies are likely to propel the segment during the forecast period.

Regional Outlook of Global Pseudomonas Aeruginosa Infection Treatment Market

Europe held a notable share of around 31% of the global pseudomonas aeruginosa infection treatment market, in terms of volume, in 2021. Europe is anticipated to account for a leading share of the global market during the forecast period, owing to an increase in the number of patients suffering from pseudomonas aeruginosa infection in the region.

North America held around 30% share of the global pseudomonas aeruginosa infection treatment market, in terms of value, in 2021. The market in the region grew at a notable growth rate due to a rise in aging population, highly structured health care industry, and availability of well-defined reimbursement policies from public and private health insurance firms, which are fueling the treatments for pseudomonas aeruginosa infection.

Middle East & Africa held a larger share of the global market as compared to that held by Latin America; however, the market in Latin America is estimated to rise at a higher growth rate as compared to the market in Middle East & Africa.

Analysis of Key Players in Global Pseudomonas Aeruginosa Infection Treatment Market

The pseudomonas aeruginosa infection treatment market report concludes with the company profiles section, which includes key information about major players in the global pseudomonas aeruginosa infection treatment market. The pseudomonas aeruginosa infection treatment market companies include ALLERGAN, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Co. and Janssen Pharmaceuticals, Inc.

Key Developments in Global Pseudomonas Aeruginosa Infection Treatment Market

In May 2021, Teva Pharmaceutical Industries Ltd. introduced erythromycin tablets with a strength of 250 mg and 500 mg. Erythromycin tablets are prescribed to treat various bacterial infections as well as rheumatic fever in patients who have an allergy to penicillin.

In February 2019, Merck announced that the FDA accepted for Priority Review a supplemental NDA for Zerbaxa to treat adult patients with nosocomial pneumonia, including ventilator-associated pneumonia, caused by certain susceptible Gram-negative microorganisms.

Each of these players has been profiled in the pseudomonas aeruginosa infection treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Pseudomonas Aeruginosa Infection Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 1.3 Bn

Market Forecast Value in 2031

US$ 2.5 Bn

Growth Rate

(CAGR) for 2022-2031

6.6%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Example: Electronic (PDF) + Excel

Market Segmentation

  • Medication Type
    • Monotherapy
    • Combination Therapy
  • Drug Type
    • Aminoglycoside
    • Cephalosporin
    • Carbapenem
    • Monobactam
    • Others
  • Route of Administration
    • Nasal
    • Oral
    • Intravenous
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC
  • South Africa

Companies Profiled

  • ALLERGAN
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Lupin Pharmaceuticals, Inc.
  • AstraZeneca
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Co.
  • Janssen Pharmaceuticals, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global pseudomonas aeruginosa infection treatment market in 2021?

The global pseudomonas aeruginosa infection treatment market was valued at US$ 1.3 Bn in 2021

How big will be the pseudomonas aeruginosa infection treatment market be in 2031?

The global pseudomonas aeruginosa infection treatment market would surpass US$ 2.5 Bn by 2031

What would the CAGR of global pseudomonas aeruginosa infection treatment market be during the forecast period (2022-2031)?

The global pseudomonas aeruginosa infection treatment market is anticipated to grow at a CAGR of 6.6% from 2022 to 2031

What is the market share of leading segment of the global pseudomonas aeruginosa infection treatment market?

The combination therapy segment held over 74% share of the global pseudomonas aeruginosa infection treatment market in 2021

Which region is likely to hold major market share during the forecast period?

Europe is expected to hold a leading share of the global market during the forecast period

Who are the prominent players in global pseudomonas aeruginosa infection treatment market?

Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb Co., AstraZeneca., and Janssen Pharmaceuticals, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Pseudomonas Aeruginosa Infection Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Medication Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecasts, 2017 - 2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Diseases Epidemiology

    5.2. Pricing Analysis

    5.3. Regulatory Scenario

    5.4. Reimbursement Scenario by Region/globally

    5.5. COVID-19 Impact Analysis

6. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Medication Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Medication Type, 2017 - 2031

        6.3.1. Monotherapy

        6.3.2. Combination Therapy

    6.4. Market Attractiveness, by Medication Type

7. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Drug Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Drug Type, 2017 - 2031

        7.3.1. Aminoglycoside

        7.3.2. Cephalosporin

        7.3.3. Carbapenem

        7.3.4. Monobactam

        7.3.5. Others

    7.4. Market Attractiveness, by Drug Type

8. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Route of Administration, 2017 - 2031

        8.3.1. Nasal

        8.3.2. Oral

        8.3.3. Intravenous

    8.4. Market Attractiveness, by Route of Administration

9. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness, by Distribution Channel

10. Global Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness, by Country/Region

11. North America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Medication Type, 2017 - 2031

        11.2.1. Monotherapy

        11.2.2. Combination Therapy

    11.3. Market Value Forecast, by Drug Type, 2017 - 2031

        11.3.1. Aminoglycoside

        11.3.2. Cephalosporin

        11.3.3. Carbapenem

        11.3.4. Monobactam

        11.3.5. Others

    11.4. Market Value Forecast, by Route of Administration, 2017 - 2031

        11.4.1. Nasal

        11.4.2. Oral

        11.4.3. Intravenous

    11.5. Market Value Forecast, by Distribution Channel, 2017 - 2031

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. Market Value Forecast, by Country, 2017 - 2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Medication Type

        11.7.2. By Drug Type

        11.7.3. By Route of Administration

        11.7.4. By Distribution Channel

        11.7.5. By Country

12. Europe Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Medication Type, 2017 - 2031

        12.2.1. Monotherapy

        12.2.2. Combination Therapy

    12.3. Market Value Forecast, by Drug Type, 2017 - 2031

        12.3.1. Aminoglycoside

        12.3.2. Cephalosporin

        12.3.3. Carbapenem

        12.3.4. Monobactam

        12.3.5. Others

    12.4. Market Value Forecast, by Route of Administration, 2017 - 2031

        12.4.1. Nasal

        12.4.2. Oral

        12.4.3. Intravenous

    12.5. Market Value Forecast, by Distribution Channel, 2017 - 2031

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Market Value Forecast, by Country, 2017 - 2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Medication Type

        12.7.2. By Drug Type

        12.7.3. By Route of Administration

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Medication Type, 2017 - 2031

        13.2.1. Monotherapy

        13.2.2. Combination Therapy

    13.3. Market Value Forecast, by Drug Type, 2017 - 2031

        13.3.1. Aminoglycoside

        13.3.2. Cephalosporin

        13.3.3. Carbapenem

        13.3.4. Monobactam

        13.3.5. Others

    13.4. Market Value Forecast, by Route of Administration, 2017 - 2031

        13.4.1. Nasal

        13.4.2. Oral

        13.4.3. Intravenous

    13.5. Market Value Forecast, by Distribution Channel, 2017 - 2031

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Market Value Forecast, by Country, 2017 - 2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis

        13.7.1. By Medication Type

        13.7.2. By Drug Type

        13.7.3. By Route of Administration

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region

14. Latin America Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Medication Type, 2017 - 2031

        14.2.1. Monotherapy

        14.2.2. Combination Therapy

    14.3. Market Value Forecast, by Drug Type, 2017 - 2031

        14.3.1. Aminoglycoside

        14.3.2. Cephalosporin

        14.3.3. Carbapenem

        14.3.4. Monobactam

        14.3.5. Others

    14.4. Market Value Forecast, by Route of Administration, 2017 - 2031

        14.4.1. Nasal

        14.4.2. Oral

        14.4.3. Intravenous

    14.5. Market Value Forecast, by Distribution Channel, 2017 - 2031

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Market Value Forecast, by Country, 2017 - 2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Medication Type

        14.7.2. By Drug Type

        14.7.3. By Route of Administration

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region

15. Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Medication Type, 2017 - 2031

        15.2.1. Monotherapy

        15.2.2. Combination Therapy

    15.3. Market Value Forecast, by Drug Type, 2017 - 2031

        15.3.1. Aminoglycoside

        15.3.2. Cephalosporin

        15.3.3. Carbapenem

        15.3.4. Monobactam

        15.3.5. Others

    15.4. Market Value Forecast, by Route of Administration, 2017 - 2031

        15.4.1. Nasal

        15.4.2. Oral

        15.4.3. Intravenous

    15.5. Market Value Forecast, by Distribution Channel, 2017 - 2031

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

    15.6. Market Value Forecast, by Country, 2017 - 2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Medication Type

        15.7.2. By Drug Type

        15.7.3. By Route of Administration

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player – Competition Matrix (By Tier and Size of companies)

    16.2. Company Profiles

        16.2.1. ALLERGAN

            16.2.1.1. Company Description

            16.2.1.2. Business Overview

            16.2.1.3. Financial Overview

            16.2.1.4. Strategic Overview

            16.2.1.5. SWOT Analysis

        16.2.2. Teva Pharmaceutical Industries Ltd.

            16.2.2.1. Company Description

            16.2.2.2. Business Overview

            16.2.2.3. Financial Overview

            16.2.2.4. Strategic Overview

            16.2.2.5. SWOT Analysis

        16.2.3. Pfizer Inc.

            16.2.3.1. Company Description

            16.2.3.2. Business Overview

            16.2.3.3. Financial Overview

            16.2.3.4. Strategic Overview

            16.2.3.5. SWOT Analysis

        16.2.4. Lupin Pharmaceuticals, Inc.

            16.2.4.1. Company Description

            16.2.4.2. Business Overview

            16.2.4.3. Financial Overview

            16.2.4.4. Strategic Overview

            16.2.4.5. SWOT Analysis

        16.2.5. AstraZeneca

            16.2.5.1. Company Description

            16.2.5.2. Business Overview

            16.2.5.3. Financial Overview

            16.2.5.4. Strategic Overview

            16.2.5.5. SWOT Analysis

        16.2.6. Merck & Co., Inc.

            16.2.6.1. Company Description

            16.2.6.2. Business Overview

            16.2.6.3. Financial Overview

            16.2.6.4. Strategic Overview

            16.2.6.5. SWOT Analysis

        16.2.7. Bristol-Myers Squibb Co.

            16.2.7.1. Company Description

            16.2.7.2. Business Overview

            16.2.7.3. Financial Overview

            16.2.7.4. Strategic Overview

            16.2.7.5. SWOT Analysis

        16.2.8. Janssen Pharmaceuticals, Inc.

            16.2.8.1. Company Description

            16.2.8.2. Business Overview

            16.2.8.3. Financial Overview

            16.2.8.4. Strategic Overview

            16.2.8.5. SWOT Analysis

List of Tables

Table 01: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031

Table 02: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 03: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031

Table 05: Global Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031

Table 08: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 09: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 10: North America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 11: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031

Table 13: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 14: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 15: Europe Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031

Table 18: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 19: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 20: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031

Table 23: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 24: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 25: Latin America Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 26: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Medication Type, 2017–2031

Table 28: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 29: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 30: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Pseudomonas Aeruginosa Infection Treatment Market, by Medication Type, 2021 and 2031

Figure 02: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031

Figure 03: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Monotherapy, 2017–2031

Figure 04: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Combination Therapy, 2017–2031

Figure 05: Global Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031

Figure 06: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 07: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Aminoglycoside, 2017–2031

Figure 08: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Cephalosporin, 2017–2031

Figure 09: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Carbapenem, 2017–2031

Figure 10: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Monobactam, 2017–2031

Figure 11: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Others, 2017–2031

Figure 12: Global Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031

Figure 13: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 14: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Nasal, 2017–2031

Figure 15: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Oral, 2017–2031

Figure 16: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Intravenous, 2017–2031

Figure 17: Global Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031

Figure 18: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 19: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 20: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 21: Global Pseudomonas Aeruginosa Infection Treatment Market (US$ Mn), by Online Pharmacies, 2017–2031

Figure 22: Global Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Region, 2021 and 2031

Figure 23: Global Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Region, 2022–2031

Figure 24: North America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 25: North America Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country, 2021 and 2031

Figure 26: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country, 2022–2031

Figure 27: North America Pseudomonas Aeruginosa Infection Treatment Market, by Medication Type, 2021 and 2031

Figure 28: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031

Figure 29: North America Pseudomonas Aeruginosa Infection Treatment Market , by Drug Type, 2021 and 2031

Figure 30: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 31: North America Pseudomonas Aeruginosa Infection Treatment Market , by Route of Administration, 2021 and 2031

Figure 32: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 33: North America Pseudomonas Aeruginosa Infection Treatment Market , by Distribution Channel, 2021 and 2031

Figure 34: North America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 35: Europe Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 36: Europe Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 37: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 38: Europe Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031

Figure 39: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031

Figure 40: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031

Figure 41: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 42: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031

Figure 43: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 44: Europe Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031

Figure 45: Europe Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 46: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 47: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 48: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 49: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031

Figure 50: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031

Figure 51: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031

Figure 52: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 53: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031

Figure 54: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 55: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031

Figure 56: Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Distribution Channel, 2022–2031

Figure 57: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 58: Latin America Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 59: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 60: Latin America Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031

Figure 61: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031

Figure 62: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031

Figure 63: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 64: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031

Figure 65: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 66: Latin America Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031

Figure 67: Latin America Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 68: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 69: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 70: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 71: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market , by Medication Type, 2021 and 2031

Figure 72: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Medication Type, 2022–2031

Figure 73: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Drug Type, 2021 and 2031

Figure 74: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

Figure 75: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Route of Administration, 2021 and 2031

Figure 76: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 77: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market, by Distribution Channel, 2021 and 2031

Figure 78: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved